Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema

April 7, 2011 By Bio-Medicine.Org

TARRYTOWN, N.Y. and BERLIN, April 8, 2011 /PRNewswire/ —
Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN
) and Bayer HealthCare today announced that they have
initiated the first of two Phase 3 clinical trials evaluating the
efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic
solution), an investigational new agent for the treatment of
certain eye diseases, in the treatment of Diabetic Macular Edema
(DME).  The companies are extending their development program
for VEGF Trap-Eye in DME after promising results in the global
Phase 2 DME program.

The first Phase 3 trial in DME, named VIVID-DME, is being led by
Bayer HealthCare and has started in Australia.  The trial will
also be conducted in Europe and Japan.  A second study led by
Regeneron, named VISTA-DME, is expected to begin later in 2011 in
the United States, Canada, and other countries.  

“Clinically significant DME is a leading cause of vision loss in
adults under the age of 50 suffering from diabetes,” said Dr. Kemal
Malik, Head of Global Development and member of the Bayer
HealthCare Executive Committee.  “After reporting positive
results from our global Phase 3 program (VIEW 1 and VIEW 2 studies)
for the treatment of the neovascular form of age-related macular
degeneration (wet AMD), we are pleased to start a Phase 3 program
with VEGF Trap-Eye in DME which may help to address this
significant unmet medical need.”

The Phase 3 program in DME expands the companies’ global
development collaboration for VEGF Trap-Eye.  The companies
announced positive data for two Phase 3 studies in patients with
wet AMD in November 2010 and for the first of two Phase 3 studies
in patients with Central Retinal Vein Occlusion (CRVO) in December
2010.

About the Phase 3 DME Program

The VIVID-DME study (VEGF Trap-Eye In
Vision Impairmen

‘/>”/>

SOURCE

Related Articles Read More >

A photo of Capstan Medical's mitral valve implant, which uses nitinol.
Capstan Medical’s R&D head discusses the heart valve and robotics startup’s tech, engineering challenges and solutions, advice for others in medtech and how to join his team
An illustration of a neurosurgeon using a robotic endoscope to remove a brain tumor.
MDO Nitinol Innovation Special Report
A photo of Highridge Medical CEO Rebecca Whitney.
Highridge Medical is betting on this spine tech
A photo of the miniature Auxilium Biotechnologies implants made on the International Space Station.
Implants 3D-printed in space could enable nerve regeneration
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe